ORKA
Price
$82.11
Change
+$4.83 (+6.25%)
Updated
Oct 9 closing price
Capitalization
5.57B
38 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$85.69
Change
+$5.79 (+7.25%)
Updated
Oct 9 closing price
Capitalization
7.56B
25 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORKA vs SYRE

ORKA vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
ORKA vs. SYRE commentary
Oct 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORKA is a Hold and SYRE is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ORKA vs SYRE: Fundamental Ratings
ORKA
SYRE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
3735
P/E GROWTH RATING
1..100
10071
SEASONALITY SCORE
1..100
5028

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORKA's Valuation (39) in the null industry is in the same range as SYRE (68) in the Pharmaceuticals Major industry. This means that ORKA’s stock grew similarly to SYRE’s over the last 12 months.

ORKA's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that ORKA’s stock grew similarly to SYRE’s over the last 12 months.

ORKA's SMR Rating (94) in the null industry is in the same range as SYRE (96) in the Pharmaceuticals Major industry. This means that ORKA’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as ORKA (37) in the null industry. This means that SYRE’s stock grew similarly to ORKA’s over the last 12 months.

SYRE's P/E Growth Rating (71) in the Pharmaceuticals Major industry is in the same range as ORKA (100) in the null industry. This means that SYRE’s stock grew similarly to ORKA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORKASYRE
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 5 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 10 days ago
87%
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
88%
COMPARISON
Comparison
Oct 11, 2026
Stock price -- (ORKA: $82.11 vs. SYRE: $85.69)
Brand notoriety: ORKA and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORKA: 171% vs. SYRE: 93%
Market capitalization -- ORKA: $5.57B vs. SYRE: $7.56B
ORKA [@Biotechnology] is valued at $5.57B. SYRE’s [@Biotechnology] market capitalization is $7.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORKA’s FA Score shows that 0 FA rating(s) are green while SYRE’s FA Score has 0 green FA rating(s).

  • ORKA’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ORKA is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORKA’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • ORKA’s TA Score: 4 bullish, 6 bearish.
  • SYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than ORKA.

Price Growth

ORKA (@Biotechnology) experienced а -2.85% price change this week, while SYRE (@Biotechnology) price change was -8.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.51%. For the same industry, the average monthly price growth was -13.43%, and the average quarterly price growth was -4.26%.

Reported Earning Dates

ORKA is expected to report earnings on Nov 18, 2026.

SYRE is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-2.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ORKA
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ENOR35.360.42
+1.20%
iShares MSCI Norway ETF (ENOR)
DFIC37.530.24
+0.64%
Dimensional International Core Equity 2 ETF (DFIC)
TUSI25.26N/A
N/A
Touchstone Ultra Short Income ETF (TUSI)
MAGG19.23N/A
N/A
Madison Aggregate Bond ETF (MAGG)
FPAS23.80N/A
N/A
FPA Short Duration Government ETF (FPAS)

ORKA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORKA
1D Price
Change %
ORKA100%
+6.25%
SYRE - ORKA
54%
Loosely correlated
+7.25%
CGON - ORKA
44%
Loosely correlated
+0.89%
XNCR - ORKA
41%
Loosely correlated
+0.53%
ENTA - ORKA
41%
Loosely correlated
+3.31%
JBIO - ORKA
41%
Loosely correlated
+1.70%
More